Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 650x65px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5496 | Ordered by Date (descending)
next pagenext page 1 2 3 4 5 6 ... 53 54 55  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
InfanDx–Arnika Beteiligungen: investment, 201904 financing round totalling up to €5.3m incl existing + co-investor Arnika Beteiligungen GmbH 2019-04-24
InfanDx–Bamed MAM Group: investment, 201904 financing round totalling up to €5.3m incl new investor Bamed MAM Group 2019-04-24
InfanDx–CVG Capital: investment, 201904 financing round totalling up to €5.3m incl new investor CVG Capital GmbH 2019-04-24
InfanDx–Life Science Inkubator: investment, 201904 financing round totalling up to €5.3m incl existing + co-investor LSI-Pre-Seed-Fonds GmbH 2019-04-24
InfanDx–SEVERAL: investment, 201904 financing round up to €5.3m milestone-based from Bamed MAM + CVG Capital + LSI PreSeed + Arnika Beteiligungen 2019-04-24
Poseida Therapeutics–Novartis: investment, 201904 financing round Series C totalling $142m incl $75m from lead investor Novartis Pharma AG 2019-04-22
Poseida Therapeutics–SEVERAL: investment, 201904 financing round Series C $142m led by Novartis with $75m 2019-04-22
Arrakis Therapeutics–HBM: investment, 201904 financing round Series B totalling $75m incl new + co- investor HBM Healthcare Investments 2019-04-18
Arrakis Therapeutics–Nextech Invest: investment, 201904 financing round Series B totalling $75m incl co-lead investor Nextech Invest 2019-04-18
Arrakis Therapeutics–SEVERAL: investment, 201904 financing round Series B $75m co-led by VenBio Partners + Nextech Invest 2019-04-18
Boehringer–PureTech Health: cancer immunotherapy, 201904– colllab research up to $226m + royalties using lymphatic targeting platform for I-O drugs 2019-04-17
Hookipa–Bank of America: financial services, 201904 supply service BofA Merrill Lynch is joint book-running manager for IPO 2019-04-17
Hookipa–RBC Capital Markets: financial services, 201904 supply service RBC Capital Markets is joint book-running manager for IPO 2019-04-17
Hookipa–Silicon Valley Bank: financial services, 201904 supply service SVP Leerink is joint book-running manager for IPO 2019-04-17
Hookipa–Van Lanschot: financial services, 201904 supply service Kempen is co-manager for IPO 2019-04-17
Bruker–Univ Nijmegen: mass spectrometry, 201904– collab establishment of joint Center of Excellence for Translational Omics at RUMC TML 2019-04-16
Cevec–SEVERAL: investment, 201904 financing round Series D from new + existing investors 2019-04-16
DNDi–Atomwise: AI-based drug discovery, 201904 collab existent €0 screening + discovery of potential drugs for Chagas disease at no cost for DNDi 2019-04-16
Univ Nijmegen–Bruker: mass spectrometer, 201904 supply existent several Bruker MS systems at RUMC TML 2019-04-16
Univ Nijmegen–Bruker: mass spectrometer, 201904c supply acquisition of timsTOF Pro IM-MS system by RUMC TML 2019-04-16
ETH Zürich–Agilent: mass spectrometer, 201904 supply new 6546 LC/Q-TOF MS system to lab of Nicola Zamboni 2019-04-15
Gilead–Novo Group: drug development, 201904– collab clinical research for NASH combining semaglutide + cilofexor + firsocostat Novo Nordisk 2019-04-12
Evotec–Indivumed: cancer drug discovery, 201904– collab strategic precision medicine for new colorectal cancer drugs 2019-04-11
BioAnalytix–Zukunftsfonds Heilbronn: investment, 201904 merger acquisition of BioAnalytix Inc by Protagen Protein Services GmbH 2019-04-10
DKSH–Bruker: analytical instruments, 201904– distribution excl extension for Bruker AXS products by DKSH in China 2019-04-09
Probiodrug–SEVERAL: investment, 201904 private placement €8.2m net €7.65m with 4.1m new shares at €2m led by Claus Christiansen et al. 2019-04-09
Phenex–Helmholtz: drug research, 201904– collab joint research in NASH + liver cancer metabolism with Heikenwälder Group at DKFZ 2019-04-05
AgomAb Therapeutics–Advent France Biotechnology: investment, 201904 financing round Series A totalling €21m incl co-lead investor Advent France 2019-04-03
AgomAb Therapeutics–Boehringer: investment, 201904 financing round Series A totalling €21m incl co-investor BIVF 2019-04-03
AgomAb Therapeutics–Omnes Capital: investment, 201904 financing round Series A totalling €21m incl co-investor Omnes 2019-04-03
AgomAb Therapeutics–Pontifax: investment, 201904 financing round Series A totalling €21m incl co-investor Pontifax 2019-04-03
AgomAb Therapeutics–SEVERAL: investment, 201904 financing round Series A €21m co-led by V-Bio Ventures + Advent France Biotechnology 2019-04-03
AgomAb Therapeutics–V-Bio Ventures: investment, 201904 financing round Series A totalling €21m incl co-lead investor V-Bio Ventures 2019-04-03
Bayer–Editas Medicine: genome editing + cell therapy, 201904– strategic research collab + cross-license CRISPR + iPSC technologies BlueRock Tx 2019-04-03
Dyne Therapeutics–Atlas Venture: investment, 201904 financing round Series A totalling $50m incl founding investor Atlas Venture 2019-04-03
Dyne Therapeutics–Forbion: investment, 201904 financing round Series A totalling $50m incl co-investor Forbion 2019-04-03
Dyne Therapeutics–MPM Capital: investment, 201904 financing round Series A totalling $50m incl co-investor MPM Capital 2019-04-03
Dyne Therapeutics–SEVERAL: investment, 201904 financing round Series A $50m from founding investor Atlas Venture plus Forbion + MPM Capital 2019-04-03
LabCorp–Qiagen: molecular companion diagnostics, 201904– collab LabCorp joins Qiagen’s Day-One Lab Readiness program 2019-04-03
Rave LLC–Bruker: investment, 201904 acquisition €na by Bruker 2019-04-03
Chr Hansen–Lonza: live biotherapeutics, 201904– collab establishment 50/50 joint venture for developing + manufacturing microbiome treatments 2019-04-02
Immunic–Rx Communications: public relations, 201904 service existent by Rx Communications Group 2019-04-02
Khloris Biosciences–Bayer: investment, 201904 seed financing €na from Leaps by Bayer 2019-04-02
IFM Therapeutics–Novartis: investment, 201904– acquisition 100% of IMF Tre for upfront payment + milestones ANNOUNCED 2019-04-01
Bayer–ProteoNic: rec protein production technology, 201903– license non-excl €na to use 2G UNic technology to boost rec protein production 2019-03-28
Polyneuron–New Enterprise Associates: investment, 201903 financing round Series A totalling CHF22.5m incl new + co-lead investor NEA 2019-03-28
Polyneuron–SEVERAL: investment, 201903 financing round Series A CHF22.5m led by Sofinnova Partners + incl NEA 2019-03-28
Polyneuron–Sofinnova: investment, 201903 financing round Series A totalling CHF22.5m incl new + lead investor Sofinnova Partners 2019-03-28
Breath Therapeutics–Canale Communications: public relations, 201903 service existent for US by Canale Communciations Inc 2019-03-26
Cytena–High-Tech Gründerfonds: investment, 201903 financing round Series A totalling €3.m incl HTGF + two private investors 2019-03-26
Cytena–SEVERAL: investment, 201903 financing round Series A €3m from HTGF + two private investors 2019-03-26
Evotec–Mark Foundation: investment, 201903–202102 research funding for two years €na by Mark Foundation with potential financial returns 2019-03-26
Menarini–Curetis: molecular diagnostics, 201903– distribution excl long-term of Unyvero platform + cartridges in Europe by Menarini Diagnostics 2019-03-26
Hookipa–SEVERAL: investment, 201903–201904 IPO $84m+$12.6m with 6m+900k shares common stock at Nasdaq Global Select Market 2019-03-22
NN–Tecan: investment, 201903–201905 acquisition $22.5m in cash of long-term supplier of precision-machined parts w production in California + Vietnam 2019-03-22
Atlatl–Miltenyi Biotec: CliniMACSProdigy platform, 201903– collab co-founding of Atlatl-Macs Center for Gene + Cell Therapy in Shanghai 2019-03-20
Oncimmune–Qiagen: investment, 201903 up to 1.34% shareholding for Qiagen after Oncimmune’s acquisition of Protagen 2019-03-19
Protagen–Oncimmune: investment, 201903 acquisition of Portagen for up to £4.11m in up to 2.636m ordinary shares 2019-03-19
Arxspan–Bruker: investment, 201903 acquisition €na of Arxspan LLC by Bruker 2019-03-14
Merck (DE)–Iktos: drug discovery services, 201903– collab using AI technology for small molecule drug discovery projects 2019-03-14
Snipr Biome–Life Sciences Partners: investment, 201903 financing round Series A totalling $50m incl co-lead investor LSP 2019-03-11
Snipr Biome–Lundbeck: investment, 201903 financing round Series A totalling $50m incl existing + co-lead investor Lundbeckfonden Emerge 2019-03-11
Snipr Biome–North-East Family Office: investment, 201903 financing round Series A totalling $50m incl co-investor North-East Family Office 2019-03-11
Snipr Biome–SEVERAL: investment, 201903 financing round Series A $50m co-led by Lundbeckfonden Emerge + Life Sciences Partners 2019-03-11
Snipr Biome–Wellington Partners: investment, 201903 financing round Series A totalling $50m incl co-investor Wellington Partners 2019-03-11
Qiagen–Tecan: lab automation, 201903– collab direct supply of Tecan Fluent workstation for sample to labs using QuantiFeron-TB Gold Plus test 2019-03-08
Gilde Investment–SEVERAL: investment, 201903 final close €200m Gilde Healthcare Service III fund incl PGGM/PF Zorg en Welzijn + Rabo Corp Investments 2019-03-07
BPCE–SEVERAL: investment, 201903 first closing €na of Seventure Health for Life Capital II Fund with final target size of over €200m 2019-03-05
Novasep–Sartorius: chromatography, 201903– collab developm of systems for membrane chromatography SSB 2019-03-05
abcr GmbH–Enzymicals: enzymes, 201903– collab distribution expansion ww sale of all catalogue products of Enzymcials by acbr 2019-03-04
NovaGo Therapeutics–Neurimmune: investment, 201903 financing round Series A totalling CHF10m incl co-lead investor + strategic partner Neurimmune 2019-03-04
NovaGo Therapeutics–Pureos Bioventures: investment, 201903 financing round Series A totalling CHF10m incl co-lead investor Pureos Bioventures 2019-03-04
NovaGo Therapeutics–SEVERAL: investment, 201903 financing round Series A CHF10m co-led by Pureos Bioventures + Neurimmune 2019-03-04
BioKryo–Air Liquide: investment, 201903c acquisition of BioKryo by Air Liquide 2019-03-01
CEPI–CureVac: mRNA vaccine production technology, 201903–202202 collab up to $34m developm of mobile mRNA printing facility 2019-03-01
Humedics–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
iOnctura–Optimum Strategic Communications: public relations, 201902 service existent by Optimum 2019-02-28
Sarepta–Centogene: molecular diagnostics, 201902–202002 collab service identifying DMD patients in MENA region by Centogene 2019-02-28
Versum Materials–Merck (DE): investment, 201902– unsolicited all-cash offer at $48/share by Merck 2019-02-27
Anaveon–Novartis: investment, 201902 financing round Series A totalling CHF35m incl co-investor Novartis Venture Fund 2019-02-26
Anaveon–SEVERAL: investment, 201902 financing round Series A CHF35m incl CHF28m from lead investor Syncona Ltd 2019-02-26
Anaveon–Wellcome Trust: investment, 201902 financing round Series A totalling CHF35m incl CHF28m from lead investor Syncona Ltd 2019-02-26
Hookipa–Invus Group: investment, 201902 financing round Series D totalling €33.2m incl new + co-investor Invus 2019-02-26
Hookipa–Redmile Group: investment, 201902 financing round Series D totalling €33.2m incl new + lead investor Redmile Group 2019-02-26
Hookipa–Samsara BioCapital: investment, 201902 financing round Series D totalling €33.2m incl new + co-investor Samsara BioCapital 2019-02-26
Hookipa–SEVERAL: investment, 201902 financing round Series D €33.2m ($37.4m) led by Redmile Group + incl Invus + Samsara Capital et al. 2019-02-26
Samsara Therapeutics–Apollo Ventures: investment, 201902 seed financing round totalling €1m incl lead investor Apollo Ventures 2019-02-26
Samsara Therapeutics–Evotec: medicinal chemistry, 201902 supply service existent compound optimisationn by Evotec 2019-02-26
Samsara Therapeutics–SEVERAL: investment, 201902 seed financing round €1m led by Apollo Ventures 2019-02-26
General Electric–Danaher: investment, 201902– acquisition $21.4b in cash of biopharma business of GE Life Sciences ANNOUNCED 2019-02-25
Roche–Citigroup: financial services, 201902 supply Citi financial advisor to Roche with regard to acquisition of Spark by Roche 2019-02-25
Roche–Davis Polk & Wardwell: legal services, 201902 supply service legal advisor to Roche w regard acquisition of Spark Therapeutics 2019-02-25
Spark Therapeutics–Centerview Partners: financial services, 201902 supply financial advisor to Spark with regard to acquisition of Spark by Roche 2019-02-25
Spark Therapeutics–Cowen: financial services, 201902 supply financial advisor to Spark with regard to acquisition of Spark by Roche 2019-02-25
Spark Therapeutics–Goodwin Procter: legal services, 201902 supply legal counsel to Spark with regard to acquisition of Spark by Roche 2019-02-25
Spark Therapeutics–Roche: investment, 201902–201912 acquisition $4.3b cash tender offer for all shares at $114.5/share 2019-02-25
Alchemist Accelerator–BASF: investment, 201902 BASF Venture Capital invests $2m + becomes Limited Partner 2019-02-20
Calypso Biotech–ABP (NL): investment, 201902 financing round Series A totalling €20m incl co-lead investor Inkef Capital 2019-02-20
Calypso Biotech–Gilde Investment: investment, 201902 financing round Series A totalling €20m incl co-lead investor Gilde Healthcare 2019-02-20
Calypso Biotech–JnJ: investment, 201902 financing round Series A totalling €20m incl co-investor JnJ Innovation JJDC 2019-02-20
next pagenext page 1 2 3 4 5 6 ... 53 54 55  next pagenext page



Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

» top